Novo Nordisk (NVO)

Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)June 8, 2026 6:42 AM
IH Market News Novo Nordisk (NYSE:NVO) shares fell 3% on Monday as investors digested new data and commercial updates presented by the company during the American Diabetes Association (ADA) conference over the weekend. While the event featured encouraging clinical findings for Novo’s next-generation diabetes therapies, analysts said the overall readout provided little that would materially alter the company’s near-term competitive position. CagriSema data highlights long-term potential A key focus of the conference was Novo Nordisk’s REIMAGINE 1-3 symposium, where the company presented new results for CagriSema in patients with Type 2 diabetes. The treatment showed what physicians described as a disease-modifying effect, with around half of patients maintaining HbA1c levels of 6.5% or lower when assessed 12 weeks after discontinuing therapy. Although healthcare professionals responded positively to the REIMAGINE-1 data, analysts noted that investors are unlikely to assign significant value to CagriSema until it moves closer to commercialization. A regulatory filing for diabetes is currently expected in late 2027, following the release of results from the REDEFINE 3 cardiovascular outcomes study. Wegovy pill prescription update raises forecast concerns Novo Nordisk also revealed that prescriptions for its oral Wegovy treatment reached 3 million in early June. However, analysis of the latest prescription data suggests there may be some downside risk to current fiscal 2026 sales forecasts for the product. Based on updated figures, analysts estimate U.S. Wegovy pill sales could reach DKK13,684 million, compared with existing projections of DKK14,289 million. That would represent a shortfall of approximately 5% for the product itself, although the impact on Novo Nordisk’s overall revenue would be less than 1%, largely due to a higher IQVIA capture rate. Conference takeaway seen as broadly neutral Market participants viewed the ADA presentations as largely incremental, providing additional detail on Novo Nordisk’s pipeline and commercial performance without delivering any major surprises. While the CagriSema results reinforced confidence in the long-term potential of the company’s diabetes portfolio, the extended timeline before commercialization appears to have limited investor enthusiasm. As a result, attention is likely to remain focused on upcoming clinical milestones and the competitive landscape within the fast-growing obesity and diabetes treatment markets. Novo Nordisk stock price Original: Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

Anyone seeing NVO possibly buy any of the three major psychedelic companies? CMPS, DFTX or ATAI?

TD Cowen Lifts GLP-1 Market Outlook, Sees Global Sales Reaching $150 Billion by 2030June 5, 2026 9:39 AM
IH Market News TD Cowen has raised its long-term forecast for the global GLP-1 market, projecting annual sales of diabetes and obesity treatments in the category will reach $150 billion by 2030. The revised estimate marks an increase from the firm’s previous forecast of $139 billion, reflecting stronger expectations for patient adoption and continued expansion of the market. Patient Numbers Expected to Grow Significantly The brokerage now anticipates that approximately 59 million people worldwide will be using GLP-1 therapies by the end of the decade. That compares with its earlier projection of 46 million patients, highlighting expectations for broader access to treatment and increasing demand for weight-management and diabetes medications. According to TD Cowen, growth in patient volumes should more than offset pricing pressures expected across the sector. Lower Prices Seen Driving Wider Adoption The firm noted that future price reductions are likely to be accompanied by substantial increases in treatment uptake. As manufacturers expand production capacity and competition intensifies, lower pricing could help make GLP-1 therapies accessible to a larger patient population, supporting continued market growth despite potential pressure on revenue per prescription. Oral Treatments Poised to Capture Larger Share TD Cowen also upgraded its outlook for oral GLP-1 medications, which are expected to become an increasingly important segment of the market. The firm now forecasts that oral formulations will account for 14% of global GLP-1 sales by 2030, compared with its previous estimate of 11%. The growing role of pill-based treatments reflects expectations that some patients and healthcare providers will favor oral alternatives over injectable therapies when clinically appropriate. Eli Lilly and Novo Nordisk Expected to Remain Dominant Despite the arrival of new competitors, TD Cowen expects the market to remain heavily concentrated among the current industry leaders. Eli Lilly (NYSE:LLY) is projected to hold approximately 62% of the global GLP-1 market by value in 2030, while Novo Nordisk (NYSE:NVO) is expected to account for roughly 31%. Together, the two pharmaceutical companies are forecast to control the overwhelming majority of industry sales as demand for obesity and diabetes treatments continues to accelerate worldwide. Obesity and Diabetes Markets Continue to Expand The revised forecast underscores growing confidence in the long-term potential of GLP-1 therapies, which have transformed treatment options for both Type 2 diabetes and obesity. With patient adoption expected to increase substantially over the coming years, the sector remains one of the fastest-growing areas within the global pharmaceutical industry. Eli Lilly stock price Novo Nordisk stock price Original: TD Cowen Lifts GLP-1 Market Outlook, Sees Global Sales Reaching $150 Billion by 2030

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)June 4, 2026 10:22 AM
IH Market News Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults. The agreement, signed on June 2, 2026, brings together Veru’s investigational therapy enobosarm and Novo Nordisk’s blockbuster weight-loss drug Wegovy. Phase 2b Study to Assess Combination Approach The PLATEAU clinical trial will evaluate the use of enobosarm alongside Wegovy (semaglutide injection) in older patients with obesity who are undergoing weight-loss treatment with Wegovy. Enobosarm is an oral selective androgen receptor modulator (SARM) that Veru is developing as part of its broader metabolic health and obesity strategy. The study is designed to examine the potential benefits of combining the two therapies in this patient population. Novo Nordisk to Supply Wegovy Under the terms of the agreement, Veru will serve as both sponsor and operator of the Phase 2b trial. Novo Nordisk will provide Wegovy for the study at no cost, supporting the clinical programme while allowing Veru to retain responsibility for trial execution and development activities. The arrangement gives Veru access to one of the leading GLP-1 obesity treatments while advancing its own clinical research efforts. Collaboration Includes Clinical Insights As part of the partnership, Veru will share knowledge and data related to obesity and weight-management studies with Novo Nordisk. This includes information regarding trial design, methodology and clinical execution, as well as regular updates covering study progress, protocol modifications and safety findings. The collaboration is intended to facilitate efficient study management while expanding understanding of combination approaches in obesity treatment. Veru Retains Global Rights to Enobosarm The company emphasized that it continues to hold full worldwide development and commercialization rights for enobosarm. However, the agreement grants Novo Nordisk a right of first negotiation should Veru seek to develop, commercialize or license intellectual property involving enobosarm in combination with any Novo Nordisk GLP-1 product for any therapeutic indication. The arrangement preserves Veru’s strategic flexibility while establishing a framework for potential future collaboration between the two companies in the growing obesity treatment market. Veru stock price Novo Nordisk stock price Original: Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (HDRN)June 4, 2026 10:22 AM
IH Market News Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults. The agreement, signed on June 2, 2026, brings together Veru’s investigational therapy enobosarm and Novo Nordisk’s blockbuster weight-loss drug Wegovy. Phase 2b Study to Assess Combination Approach The PLATEAU clinical trial will evaluate the use of enobosarm alongside Wegovy (semaglutide injection) in older patients with obesity who are undergoing weight-loss treatment with Wegovy. Enobosarm is an oral selective androgen receptor modulator (SARM) that Veru is developing as part of its broader metabolic health and obesity strategy. The study is designed to examine the potential benefits of combining the two therapies in this patient population. Novo Nordisk to Supply Wegovy Under the terms of the agreement, Veru will serve as both sponsor and operator of the Phase 2b trial. Novo Nordisk will provide Wegovy for the study at no cost, supporting the clinical programme while allowing Veru to retain responsibility for trial execution and development activities. The arrangement gives Veru access to one of the leading GLP-1 obesity treatments while advancing its own clinical research efforts. Collaboration Includes Clinical Insights As part of the partnership, Veru will share knowledge and data related to obesity and weight-management studies with Novo Nordisk. This includes information regarding trial design, methodology and clinical execution, as well as regular updates covering study progress, protocol modifications and safety findings. The collaboration is intended to facilitate efficient study management while expanding understanding of combination approaches in obesity treatment. Veru Retains Global Rights to Enobosarm The company emphasized that it continues to hold full worldwide development and commercialization rights for enobosarm. However, the agreement grants Novo Nordisk a right of first negotiation should Veru seek to develop, commercialize or license intellectual property involving enobosarm in combination with any Novo Nordisk GLP-1 product for any therapeutic indication. The arrangement preserves Veru’s strategic flexibility while establishing a framework for potential future collaboration between the two companies in the growing obesity treatment market. Veru stock price Novo Nordisk stock price Original: Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (HDRN)

Novo Nordisk Expands Wegovy Rollout with Launch of Weight-Loss Pill in UAE (NVO)June 3, 2026 6:21 AM
IH Market News Novo Nordisk (NYSE:NVO) has introduced the tablet form of its blockbuster obesity treatment Wegovy in the United Arab Emirates, marking the second country worldwide to receive the oral version of the medication. The launch follows regulatory approval granted earlier this week by health authorities in the UAE and comes several months after the Danish pharmaceutical group debuted the product in the United States. UAE Becomes Second Market for Oral Wegovy The Emirates Drug Establishment authorized the once-daily weight-management pill after evaluating clinical evidence demonstrating its effectiveness in helping patients achieve meaningful weight loss and maintain reductions over the long term when combined with healthy lifestyle measures. Regulators also highlighted the treatment’s ability to lower the risk of major adverse cardiovascular events in eligible patient populations, further strengthening its role in obesity management. The approval represents another step in Novo Nordisk’s efforts to broaden access to its obesity therapies beyond injectable treatments. Growing Focus on Long-Term Obesity Care Novo Nordisk said future market launches for the oral formulation will be determined by several factors, including patient demand, healthcare system readiness and the availability of infrastructure needed to support long-term obesity treatment. The company is assessing markets based on both medical need and the capacity of healthcare providers to manage patients receiving ongoing weight-management therapies. Additional International Launches Expected Emil Kongshoj Larsen, Head of International Operations at Novo Nordisk, indicated that the UAE met the key requirements the company considers when introducing new obesity treatments. “The UAE has demonstrated strong momentum across all of these areas, and we look forward to bringing Wegovy pill to additional select countries in the coming months,” Larsen said. The launch underscores Novo Nordisk’s broader strategy of expanding the global availability of Wegovy as demand for obesity treatments continues to grow across both developed and emerging healthcare markets. Novo Nordisk stock price Original: Novo Nordisk Expands Wegovy Rollout with Launch of Weight-Loss Pill in UAE (NVO)

Eli Lilly shares rise after strong late-stage obesity drug trial results (LLY)May 21, 2026 8:49 AM
IH Market News Eli Lilly (NYSE:LLY) shares gained around 2% in premarket trading on Thursday after the company released positive late-stage clinical trial results for its experimental obesity treatment retatrutide.The study showed that patients diagnosed with obesity lost an average of 28.3% of their body weight over an 80-week period when treated with the highest 12-milligram dose of retatrutide.More than 45% of participants achieved weight loss of at least 30% during the trial.The results strengthen Eli Lilly’s path toward seeking regulatory approval for the drug, with a potential commercial launch possible next year.The study focused on patients with obesity who did not have diabetes.Retatrutide is the first obesity treatment developed by Lilly that targets three separate hormone receptors simultaneously: GLP-1, which helps suppress appetite; GIP, which supports insulin secretion; and glucagon, which assists with fat burning.Earlier clinical studies suggested the drug could deliver greater weight reduction than Lilly’s injectable obesity medication Zepbound as well as Novo Nordisk’s (NYSE:NVO) Wegovy.The late-stage trial enrolled adults living with obesity or individuals classified as overweight who also had at least one weight-related health condition.Kenneth Custer, president of cardiometabolic health at Eli Lilly, said the 30% weight-loss benchmark “is really a threshold that’s historically been associated with bariatric surgery. To have that available in a medicine is a pretty big deal.”The latest results mark another significant step in Eli Lilly’s efforts to strengthen its position within the rapidly expanding obesity drug market.Eli Lilly stock priceNovo Nordisk stock price Original: Eli Lilly shares rise after strong late-stage obesity drug trial results (LLY)

Novo Nordisk (NVO) Reports Strong Weight-Loss Results for Higher-Dose WegovyMay 12, 2026 10:43 AM
IH Market News Novo Nordisk (NYSE:NVO) unveiled new clinical data on Tuesday showing that a higher 7.2 mg dose of Wegovy delivered substantial weight loss in people with obesity, regardless of how rapidly patients initially responded to treatment.The findings were presented at the European Congress on Obesity in Istanbul. STEP UP Trial Shows Greater Weight Loss With Higher Dose The company’s STEP UP trial evaluated semaglutide at a 7.2 mg dose versus the standard 2.4 mg dose and placebo over a 72-week period in more than 1,400 adults living with obesity who did not have type 2 diabetes.Participants receiving the 7.2 mg dose lost an average of 21% of their total body weight during the study.For the average participant, who weighed 113 kilograms before treatment, this equated to approximately 23 kilograms of weight loss.Patients taking the 2.4 mg dose experienced average weight loss of around 17.5% over the same period, while those receiving placebo lost 2.4%. Early Responders Achieved Even Greater Weight Reduction Researchers classified early responders as participants who lost at least 15% of their body weight within the first 24 weeks of treatment.Among patients receiving the 7.2 mg dose, approximately 27% met the criteria for an early response, compared with 21% of patients taking the 2.4 mg dose and 3% in the placebo group.The early responder subgroup treated with the 7.2 mg dose achieved average weight loss of 27.7% by week 72. Data Suggests Majority of Weight Loss Came From Fat Reduction A separate body composition analysis involving 55 participants indicated that roughly 84% of weight lost during semaglutide treatment came from reductions in fat mass.The study also found that abdominal visceral fat declined by more than 30% among participants receiving semaglutide.Muscle mass decreased by approximately 10% compared with baseline levels, although researchers said muscle health improved based on lower levels of fat infiltration within muscle tissue. Functional Muscle Strength Was Preserved During Treatment Novo Nordisk said participants maintained functional muscle strength throughout the weight-loss process.Researchers evaluated muscle function using a 30-second sit-to-stand test, which showed similar functional muscle strength before and after treatment in both the semaglutide and placebo groups.Novo Nordisk stock price Original: Novo Nordisk (NVO) Reports Strong Weight-Loss Results for Higher-Dose Wegovy

The $59B Quiet Shift Reshaping How Patients Access CareMay 12, 2026 10:30 AM
PR Newswire (US) Issued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and five names sit at the center of that structural realignment: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).  The trajectory keeps steepening. Analysts project the global POC diagnostics market will reach $114.65 billion by 2035, fueled by AI integration, miniaturized biosensors, and cloud-connected platforms that compress turnaround times from days to minutes[3]. The entire diagnostic equipment value chain is shifting from a centralized hospital model to a decentralized, consumer-facing landscape, and that creates a scalable opening for platforms delivering accessible, clinical-grade outcomes outside traditional hospital walls.VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is heading to Europe next week to showcase its AI-powered cardiac imaging platform at one of the biggest cardiology conferences on the planet. The company will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), running May 12 to 16 in Padua, Italy, alongside European distributor AngioPro. AEPC is the world's largest association in congenital cardiology, with over 1,000 specialists across 32 countries, and this year's program is centered on cardiovascular imaging and artificial intelligence, exactly the areas where VentriPoint operates.VMS+™ 4.0 takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to cardiac MRI, but without the million-dollar machine or the months-long wait list. Built on more than a decade of proprietary Knowledge Based Reconstruction technology, the system works with ultrasound equipment from any manufacturer and holds regulatory approvals in the United States, Canada, and Europe.That regulatory footprint is expanding. In late April, VentriPoint announced that strategic partner Lishman Global Inc. formally submitted VMS+™ 4.0 to China's National Medical Products Administration (NMPA) for approval. Lishman Global qualified for the NMPA's expedited "green channel" review pathway, reserved for innovative technologies addressing significant clinical needs. China has an estimated 330 million patients affected by cardiovascular disease.Commercial momentum has been building. VentriPoint recently picked up a Gold Medal at the 2026 Edison Awards for VMS+™ 4.0. It announced a collaboration with the Health Division of the Montecristo Group to deploy VMS+™ across Costa Rica's hospital networks, where Hospital Metropolitano has an existing relationship with Sanford Health. VentriPoint also recently partnered with First Light Health to bring cardiac diagnostics to Indigenous and remote communities across Canada, building on an earlier partnership with the Nisga'a Valley Health Authority. The company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of VentriPoint. "VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI, giving clinicians the confidence they need to manage their patients at every stage of life."With regulatory submissions advancing in China, distribution partners spanning Costa Rica to Northern California, Edison Award recognition, and a growing presence at major cardiology conferences, VentriPoint is building the kind of global footprint that turns a promising medtech platform into a scalable business.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/Other industry developments and happenings in the market include:Hims & Hers Health (NYSE: HIMS) announced a new collaboration with Novo Nordisk to make a broad assortment of FDA-approved GLP-1 medications available to eligible customers, including Wegovy, the only FDA-approved GLP-1 weight loss pill. The expansion positions Hims & Hers Health as the largest global consumer health platform for affordable access to approved medications, with prices starting as low as $149 a month."Today we're taking an important next step toward building a better model of healthcare that works for everyday people," said Andrew Dudum, co-founder and CEO of Hims & Hers Health. "When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we're thrilled to be working alongside Novo Nordisk to help more people feel their best and we're excited to find more ways to collaborate across the industry."Novo Nordisk (NYSE: NVO) is expanding patient reach through the partnership, with eligible customers now able to access treatments that can help them lose up to 20% of their body weight. Multiple Wegovy dosing options are available across both injectable and pill formats, alongside Ozempic injection pens approved for Type 2 diabetes treatment."Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient," said Dr. Craig Primack, SVP Weight Management at Hims & Hers Health. "As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We're excited to see how our customers succeed as more innovative treatments become available."MannKind (NASDAQ: MNKD) announced it will present new clinical data on Afrezza at the ATTD 2026 conference in Barcelona, spanning oral and poster sessions focused on real-world dosing patterns and post-prandial glucose management in both adult and pediatric patients with type 1 diabetes. The presentations include findings from the INHALE-1 study, which examined how inhaled insulin is initiated and adjusted in children and adolescents, with patients started at an approximately 2:1 conversion from rapid-acting insulin analogs."We look forward to presenting important new data for Afrezza at this year's ATTD and contributing to the scientific dialogue around meal-time diabetes management across both adult and pediatric populations," said Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head, Diabetes for MannKind. "ATTD is a key forum for advancing how clinicians think about insulin use at meals, and we value the opportunity to engage with the global diabetes community on this important topic."The FDA accepted a supplemental Biologics License Application for Afrezza in patients ages 4-17 living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, Afrezza would become the first needle-free insulin option for pediatric patients in over 100 years.Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab, a browser-based interface that gives researchers remote access to the company's autonomous lab infrastructure powered by proprietary Reconfigurable Automation Carts. The platform connects scientists to a fleet of over 70 instruments spanning sample preparation, liquid handling, analytical readouts, storage, and incubation, with an AI-driven agent called EstiMate enabling protocol submission in plain language and immediate compatibility assessment and pricing."Autonomous labs are poised to scale and accelerate the high-mix work that a lab bench supports," said Jason Kelly, CEO of Ginkgo Bioworks. "By opening up our autonomous infrastructure through the Cloud Lab, we're giving scientists access to these tools today."Ginkgo Cloud Lab is central to Ginkgo Bioworks' 2026 strategic shift to consolidate all R&D services onto Nebula, its autonomous lab in Boston, MA, decommissioning traditional benches in favor of programmable robotic infrastructure. The company is targeting users ranging from academic researchers to global biopharmaceutical companies, inviting them to submit protocols directly at cloud.ginkgo.bio for feasibility reports and price quotes.Further Reading: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/CONTACT:
Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.mordorintelligence.com/industry-reports/point-of-care-diagnosticshttps://www.medtechdive.com/news/digital-health-funding-concentrates-fewer-startups-q1-2026-rock-health/816933/ https://www.globenewswire.com/news-release/2026/04/30/3285062/0/en/Global-Point-of-Care-Diagnostics-Market-Size-Set-to-Reach-USD-114-65-Billion-by-2035-SNS-Insider.html Logo: https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg View original content:https://www.prnewswire.com/news-releases/the-59b-quiet-shift-reshaping-how-patients-access-care-302769492.html Original: The $59B Quiet Shift Reshaping How Patients Access Care

Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strongMay 6, 2026 6:35 AM
IH Market News Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its obesity and diabetes treatments despite softer underlying first-quarter results caused by pricing pressure.The pharmaceutical group said it now expects adjusted sales and operating profit for 2026 to decline between 4% and 12% at constant exchange rates, representing a narrower contraction than previously anticipated and reflecting stronger expectations for its GLP-1 treatment portfolio.Shares in the Danish drugmaker climbed 7% in early trading in Copenhagen. First-quarter results boosted by one-off U.S. pricing adjustment Operating profit in the first quarter jumped 65% to 59.6 billion Danish crowns ($8.6 billion), supported by a one-time reversal related to the U.S. 340B Drug Pricing Program.However, on an adjusted basis, operating profit fell 6% to 32.9 billion crowns, while adjusted revenue declined 4% to 70.1 billion crowns as lower realised prices offset growth in sales volumes. Wegovy continues to drive obesity treatment growth Sales of obesity therapies remained a key growth driver for the company, rising 22% at constant exchange rates, helped by continued demand for Wegovy.The newly launched oral version of Wegovy in the United States generated quarterly sales of 2.3 billion Danish crowns.Adjusted sales in the U.S. market declined 11% because of pricing headwinds, while international sales increased 6% on the back of stronger volumes. Analysts remain optimistic on guidance outlook “We continue to see the bottom end of the guidance as conservative and expect Novo to finish the year in the upper half of the guidance,” analysts at Morgan Stanley said in a research note.Novo Nordisk stated that broader access to GLP-1 medicines and ongoing product launches should continue to support growth, although increased competition, pricing pressure and patent expirations are expected to weigh on performance during the remainder of the year.Novo Nordisk stock price Original: Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong

Novo Nordisk’s Weight-Loss Pill Momentum Faces Pricing PressureMay 5, 2026 6:27 AM
IH Market News Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U.S. rival Eli Lilly and Company (NYSE:LLY) is raising concerns about whether growing prescription volumes can offset mounting pricing pressure in the obesity drug market.The Danish drugmaker is set to report first-quarter earnings on Wednesday, with a heavy focus on the pill’s performance as it seeks to regain market share. The broader outlook for obesity treatments has become less certain, as U.S. pricing declines and increased competition challenge earlier projections of a $150 billion global market within the next decade. A Critical Moment for Novo The company has spent much of the past year under pressure, following setbacks including underwhelming trial results for its next-generation obesity treatment, reduced guidance, leadership changes and a significant share price decline that has erased more than $400 billion in market value since its 2024 peak.“We are in the middle of the exam period, let’s put it that way,” said Mikael Bak, head of the Danish Shareholders’ Association.“What I will be looking for is whether they are increasingly able to go from being rather defensive to being more offensive.” Strong Early Demand for Oral Wegovy Initial prescription data for Novo’s oral Wegovy treatment has exceeded expectations. According to figures from research firm IQVIA Holdings Inc., around 721,000 prescriptions were recorded in the U.S. during the first quarter, noted BMO Capital Markets analyst Evan Seigerman.However, Novo’s first-mover advantage ended in early April when Eli Lilly secured approval for its competing pill, Foundayo, setting up direct competition in the oral obesity segment.In a potentially encouraging sign for the sector, Eli Lilly recently reported stronger-than-expected quarterly results, boosting both its own shares and those of Novo, supported by robust demand for its weight-loss and diabetes treatments Zepbound and Mounjaro. Volume Growth vs Revenue Pressure Seigerman cautioned that it may be too early to draw firm conclusions from the initial launch data, noting that IQVIA figures exclude some prescriptions filled through telehealth providers, suggesting actual patient numbers could be higher.At the same time, analysts warn that strong prescription volumes may not translate into equally strong revenue. Approximately 450,000 prescriptions were for the lowest 1.5 mg starter dose, priced at $149 per month. BMO Capital Markets estimates that first-quarter pill revenue could fall about 12% short of the roughly $1 billion consensus forecast.“The initial launch has gone better than people thought,” said Barclays analyst James Gordon. “But are some people just starting on the cheap low dose and staying on it because it’s cheaper and they don’t need the higher efficacy and cost delivered by higher doses? There are still quite a lot of moving parts, even before Lilly’s competing oral product makes an impact”.Patients typically begin treatment at lower doses and gradually move higher over time. A slower transition to higher doses could weigh on revenue even if prescription growth remains strong.Novo declined to comment ahead of its results due to regulatory restrictions.Gordon added that prescriptions for the starter dose appear to have plateaued, while uptake of higher doses has been slower than expected. He suggested that some patients may be remaining on lower-cost doses longer, while others may be discontinuing treatment altogether. Pricing Pressures Build Novo shareholder Lukas Leu acknowledged the strong initial launch but highlighted risks from intensifying price competition, particularly as rivals expand and U.S. President Donald Trump pushes to lower drug costs.“The launch is definitely strong – I think no one wants to debate about that,” Leu said. “What we don’t know yet is whether it will compensate Novo for the price decline, which is faster.”Some investors expect Novo to maintain its full-year guidance while waiting for clearer data on how the pill performs against Eli Lilly’s rival product. Others anticipate a possible increase at the lower end of the forecast range. Competition with Eli Lilly in Focus Investor sentiment toward Novo is increasingly shaped by comparisons with Eli Lilly, with some arguing the U.S. company has moved more decisively in advancing its pipeline and executing strategic deals.“We see early but preliminary signs of progress. But it is still early stage – the future will show whether it is actually enough,” said Anders Schelde of AkademikerPension.Novo Nordisk stock priceEli Lilly stock price Original: Novo Nordisk’s Weight-Loss Pill Momentum Faces Pricing Pressure

$NVO Sold small profit was down alot last few days.

If i had 100,000 or whatever I would place it in $NVO wait a few months.

Im getting upset nobody buying $NVO it way below its fair value and will soon uptrend like it was a week ago.

Bought 126 Shares at 40.96 $NVO about to cross 50MA and uptrend more. Way to cheap sold off to its limit based on financials.

Novo Nordisk Teams Up With OpenAI to Accelerate Drug DevelopmentApril 14, 2026 6:05 AM
IH Market News
Novo Nordisk (NYSE:NVO) said Tuesday it has entered into a strategic collaboration with OpenAI to deploy advanced artificial intelligence tools across its business, spanning drug discovery through to commercial operations.The Danish pharmaceutical group said the partnership will support the analysis of complex datasets, help identify potential drug candidates, and shorten the timeline from early-stage research to patient access. It added that the initiative will operate under strict safeguards, including data protection, governance frameworks, and human oversight.“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare,” said Mike Doustdar. He added that millions of people living with obesity and diabetes require improved treatment options, and that integrating AI will enable the company to process data at unprecedented scale and test scientific hypotheses more rapidly.OpenAI will also support workforce development at Novo Nordisk by enhancing AI-related skills and literacy across its global employee base. In addition, the collaboration will extend to improving efficiency in manufacturing, supply chains, distribution, and broader corporate functions.Initial pilot projects are set to roll out across research and development, manufacturing, and commercial units, with full implementation targeted by the end of 2026.“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” said Sam Altman. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”The agreement builds on Novo Nordisk’s existing AI efforts, which already include partnerships with technology firms and research institutions. The company employs around 68,800 people across 80 countries and sells its products in approximately 170 markets worldwide.Novo Nordisk stock price

Original: Novo Nordisk Teams Up With OpenAI to Accelerate Drug Development

UK regulator recommends Novo Nordisk’s Wegovy to help reduce cardiovascular risksApril 1, 2026 10:03 AM
IH Market News
In a significant regulatory move, the UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Novo Nordisk’s (NYSE:NVO) Wegovy to help prevent major cardiovascular events, including heart attacks and strokes.The guidance applies to adults who are living with obesity or who are overweight, and marks the first time a GLP-1 therapy has been formally endorsed for reducing cardiovascular risk, rather than being limited to treating diabetes or supporting weight loss.Novo Nordisk said on Wednesday that the 2.4 mg dose of Wegovy will now be made available through the UK’s National Health Service (NHS).The company added that the treatment is expected to be incorporated into existing cardiovascular care pathways, expanding its role in the management of heart-related health risks.Novo Nordisk stock price

Original: UK regulator recommends Novo Nordisk’s Wegovy to help reduce cardiovascular risks

Novo Nordisk introduces discounted Wegovy subscription plan in the U.S.March 31, 2026 10:46 AM
IH Market News
Novo Nordisk (NYSE:NVO) has rolled out a new subscription-based pricing program in the United States aimed at patients paying out of pocket for Wegovy without insurance coverage. The initiative provides monthly discounts of up to 29% through several telehealth providers.Beginning Tuesday, eligible self-pay patients can obtain three-, six-, or 12-month supplies of Wegovy at fixed monthly prices via telehealth platforms including Ro, WeightWatchers, and LifeMD. Additional digital health providers such as Hims & Hers and Sesame are expected to participate in the program in the near future.Under the new pricing structure, Wegovy injection pens are offered at $329 per month for a three-month plan, $299 per month for a six-month plan, and $249 per month for a 12-month subscription. These prices represent discounts ranging from 6% to 29% compared with the standard $349 monthly price. The oral version of Wegovy is priced at $289, $269, and $249 per month for the same subscription durations, reflecting discounts of roughly 3% to 17% from the typical $299 monthly cost.Ed Cinca, Novo’s senior vice president of marketing and patient solutions, said patients were seeking “easier and clearer ways of facilitating payment” for obesity management. He added that individuals paying out of pocket are looking for predictable costs and straightforward pricing.Meanwhile, rival drugmaker Eli Lilly (NYSE:LLY) offers its own self-pay program for the competing obesity treatment Zepbound, with prices starting at $299 per month for the 2.5 mg dose, $399 for the 5 mg dose, and $449 for 7.5 mg and higher doses under its Self Pay Journey Program. Lilly is also awaiting a decision from the U.S. Food and Drug Administration on its oral obesity treatment candidate, with approval expected in the second quarter.Novo Nordisk stock priceEli Lilly stock price

Original: Novo Nordisk introduces discounted Wegovy subscription plan in the U.S.

Weight Watchers introduces discounted Wegovy pricing through Novo Nordisk partnershipMarch 31, 2026 10:53 AM
IH Market News
WW International Inc. (NASDAQ:WW) said its Med+ members will gain access to reduced pricing for Wegovy through an expanded collaboration with Novo Nordisk (NYSE:NVO), lowering out-of-pocket costs for patients paying without insurance.The program gives Weight Watchers Med+ members access to subscription-based pricing for Wegovy doses, potentially delivering savings of up to $1,200 per year for individuals paying in cash. The initiative aligns with Novo Nordisk’s recently introduced subscription pricing model for the obesity treatment.Eligible Med+ members who have valid prescriptions can prepay for three-, six-, or 12-month supplies of Wegovy at discounted monthly rates. The program applies to Wegovy injection pens across all dosage levels and Wegovy tablets at 9 mg and 25 mg doses. Depending on the length of the commitment, members may save up to $100 per month on injection pens and up to $50 per month on tablets compared with standard self-pay pricing.“Novo Nordisk and Weight Watchers are each committed to helping those living with obesity take control of their health–and we are strengthening our collaboration to support that shared mission,” said Ed Cinca, Senior Vice President Marketing and Patient Solutions at Novo Nordisk.Members who do not opt for multi-month plans can still access current promotional offers, including introductory Wegovy tablet doses priced at $149 per month. Weight Watchers participates in the NovoCare program as a Recognized Care Provider.The Weight Watchers Med+ platform connects members with board-certified physicians, access to FDA-approved prescriptions, and structured lifestyle programs. Its GLP-1 Success initiative provides additional tools and guidance throughout a patient’s treatment journey.The company said its clinical services segment is expanding rapidly as demand rises for integrated GLP-1-based weight management programs. The strengthened partnership with Novo Nordisk builds on the companies’ existing collaboration to broaden access to approved treatments for obesity management.WW International stock priceNovo Nordisk stock price

Original: Weight Watchers introduces discounted Wegovy pricing through Novo Nordisk partnership

Novo Nordisk and United Laboratories report encouraging phase 2 results for diabetes drug UBT251March 25, 2026 6:54 AM
IH Market News
Novo Nordisk A/S (NYSE:NVO) and The United Laboratories International Holdings Limited said Wednesday that their jointly developed treatment UBT251 delivered strong improvements in blood glucose control and weight reduction in a phase 2 clinical trial involving Chinese patients with type 2 diabetes.The study evaluated UBT251, a triple agonist designed to activate GLP-1, GIP and glucagon receptors, in 211 Chinese patients over a 24-week period. Participants received once-weekly injections of either 2 mg, 4 mg or 6 mg of UBT251, with results compared against a placebo group and patients receiving 1 mg of semaglutide.Patients receiving the highest 6 mg dose recorded an average HbA1c reduction of 2.16% from a starting level of 8.12%. By comparison, those treated with semaglutide 1 mg saw a 1.77% reduction, while the placebo group recorded a decline of 0.66%. HbA1c reflects average blood glucose levels over time and is a key benchmark in managing diabetes.The trial also produced notable weight-loss outcomes. Patients treated with UBT251 experienced average body weight reductions of up to 9.8% from a baseline of 80.1 kg, compared with a 4.8% reduction among patients taking semaglutide and 1.4% in the placebo group.Researchers also observed improvements in waist circumference, blood pressure and lipid levels among participants receiving UBT251 relative to placebo. According to the companies, the treatment’s safety profile was consistent with previous studies involving triple agonist therapies.“Following the recent positive read-out of phase 2 data in people with overweight or obesity, we are encouraged to see the results of this trial, which also demonstrate the potential of UBT251 in a type 2 diabetes population,” said Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk.The clinical study was conducted by United Biotechnology, a subsidiary of United Laboratories, which holds development rights for UBT251 across mainland China, Hong Kong, Macau and Taiwan. Novo Nordisk retains development and commercialization rights for the rest of the world under a partnership agreement signed in March 2025.Novo Nordisk said it plans to begin a global phase 2 trial of UBT251 in patients with type 2 diabetes during the second half of 2026. The company is already running a separate global phase 2 study examining the drug’s use in weight management, with results expected in 2027.United Biotechnology plans to present detailed findings from the study at a medical conference later this year and intends to launch two phase 3 trials in Chinese patients with type 2 diabetes based on the encouraging phase 2 results.Novo Nordisk stock price

Original: Novo Nordisk and United Laboratories report encouraging phase 2 results for diabetes drug UBT251

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profileMarch 19, 2026 12:04 PM
PR Newswire (US)

Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial.1,2 Wegovy® HD can be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated. This new update supplements the existing Wegovy® label, which also has distinct indications for Wegovy® not offered by any other GLP-1 medication for weight loss.2"We are excited to bring Wegovy® HD injection to adults with obesity who are looking for powerful weight loss, as no other weight loss medicine has been studied to show superiority to Wegovy® HD," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "In addition to significant weight loss, Wegovy® is the only GLP-1 for adults with obesity that is proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease. Today's milestone expands the strong clinical profile of Wegovy® that includes multiple indications that no other GLP-1 for weight loss can claim."Prior to this approval, the highest approved dose of Wegovy® injectable for weight loss was 2.4 mg, which is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.2The FDA approval of Wegovy® HD is based on the results of the STEP UP trial program, which included STEP UP, a 72-week study which evaluated the efficacy and safety of once-weekly Wegovy® 7.2 mg compared to placebo and Wegovy® 2.4 mg, as an adjunct to lifestyle intervention in 1,407 adults with obesity (BMI 30 kg/m2 or greater), without diabetes.1,3STEP UP Trial Results (at 72 weeks1, 2) 
Wegovy® injection  
7.2 mgWegovy® injection
2.4 mgPlaceboAverage
weight
reduction1If all patients stayed
on treatment(Efficacy 
estimand*)~21% (20.7%)~18% (17.5%)~2% (2.4%)Analysis of all
patients regardless
of whether they
stayed on treatment2(Treatment regimen
estimand**)~19% (18.8%)~16% (15.5%)~4% (3.9%)
Percent of patients
who achieved 25% or
more weight loss**31.2 %15.3 %0 %Based on a mean baseline body weight of 248 lb. for Wegovy® injection 7.2 mg and placebo groups, and 257 lb. for the Wegovy® 2.4 mg group.The most common adverse reactions reported with Wegovy® HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence. In clinical trials, dysesthesia was reported at a higher rate with Wegovy® HD compared to Wegovy® 2.4 mg and placebo.2 Events related to a clinical picture of altered skin sensation such as sensitive skin, hyperesthesia, dysesthesia and paresthesia were reported by a higher proportion of participants, and at a higher rate, in the Wegovy® HD arm (22%), compared to treatment with Wegovy® 2.4 mg (6%) and placebo (0.3%).2"Wegovy® HD represents an important new tool in obesity management, allowing clinicians to better tailor treatment strategies and help improve outcomes," said W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. "The weight loss demonstrated with Wegovy® HD could reshape healthcare professionals' expectations about what outcomes are possible for their patients with Wegovy®."Wegovy® HD will be available in April through all channels where patients can access Wegovy® including 70,000 plus pharmacies in the US like CVS and Costco, select telehealth providers, NovoCare® Pharmacy, GoodRx, and others. Additional information on coverage and savings options for eligible patients, including other programs designed to help reduce out-of-pocket costs, will also be available at that time.* Based on the efficacy estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies.
** Based on the treatment regimen estimand: treatment effect regardless of whether patients stayed on treatment or took other weight loss therapies.About the STEP UP trial
STEP UP was a phase 3b 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention.1 1,407 adults with BMI ≥30 kg/m2 without diabetes were included in the trial. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss after 72 weeks with respect to the percentage change in body weight and the proportion of participants achieving weight loss of 5% or greater.1 Select confirmatory secondary endpoints included number of participants achieving ≥10%, 15%, 20% and 25% weight loss, with semaglutide 7.2 mg vs placebo (and for greater than or equal to 20% and 25%, semaglutide 7.2 mg vs semaglutide 2.4 mg).1 In total, 1,407 participants were randomized in a 5:1:1 ratio to receive once-weekly subcutaneous semaglutide 7.2 mg, 2.4 mg, or placebo, alongside lifestyle intervention, for 72 weeks.1 For those taking Wegovy® HD, 89% achieved 5% or greater body weight loss versus 38% taking placebo (from a baseline body weight of 248 lb.).**About obesity 
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8What is Wegovy®?Wegovy® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.Wegovy® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.It is not known if Wegovy® injection is safe and effective:to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 yearsto help children under 12 years of age lose weight and keep the weight offIt is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.Important Safety InformationWhat is the most important information I should know about Wegovy®?
Wegovy® may cause serious side effects, including:Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and other medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in peopleDo not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Do not use Wegovy® if:you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® injection or Wegovy® tablets.  See symptoms of serious allergic reaction in "What are the possible side effects of Wegovy®?"Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:have or have had problems with your pancreas or kidneyshave type 2 diabetes and a history of diabetic retinopathyare scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnantare breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy® tablets. It is not known if Wegovy® when received through an injection passes into your breast milkTell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.What are the possible side effects of Wegovy®?
Wegovy® may cause serious side effects, including:inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your backgallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stoolsincreased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jitterydehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go awaysevere stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go awayserious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeatchange in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy® increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutesfood or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other proceduresThe most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy®. About Novo Nordisk
Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.?With a US presence spanning 40 years, Novo Nordisk US is headquartered in?New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D and corporate locations in eight states plus?Washington, D.C. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.Contacts for further informationMedia:
Liz Skrbkova (US)
+1 609 917 0632USMediaRelations@novonordisk.com
Ambre James-Brown (Global)
+45 3079 9289
Globalmedia@novonordisk.com

Investors:
Frederik Taylor Pitter (US)+1 609 613 0568
fptr@novonordisk.comJacob Martin Wiborg Rode (Global)
+45 3075 5956
jrde@novonordisk.com

Sina Meyer (Global)+45 3079 6656
azey@novonordisk.comChristoffer Sho Togo Tullin (Global)
+45 3079 1471cftu@novonordisk.com

Max Ung (Global)
+45 3077 6414
mxun@novonordisk.comAlex Bruce (Global)+45 34 44 26 13
axeu@novonordisk.comReferences:Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963.Wegovy® (semaglutide) Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.Lingvay I, Bergenheim S, Buse J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948.Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61–69.Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: March 2026. Available at: https://www.cdc.gov/obesity/adult-obesity-facts/index.htmlCenters for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: March 2026. Available at: https://www.cdc.gov/obesity/risk-factors/risk-factors.html.© 2026 Novo Nordisk All rights reserved. US26SEMO00066 March 2026 





View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.htmlSOURCE NOVO NORDISK INC.

Original: FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

GLOBAL PATIENT ALERT: THE OZEMPIC WITHDRAWAL SCANDAL – SYSTEMIC NEGLIGENCE & LACK OF INFORMED CONSENT
The pharmaceutical hype surrounding Ozempic (Semaglutide) has hidden a dark reality: a total failure to warn patients about life-threatening withdrawal symptoms. We are witnessing a predatory system where corporate profit is prioritized over human lives, and medical ethics are being discarded as "collateral damage."

1. The Missing Warning: Life-Threatening Hypertension
Official documentation for Ozempic (both FDA and EMA labels) is fundamentally flawed. It lists minor side effects but completely ignores the Rebound Hypertension crisis. Patients—like my own sister—who stop the medication are suffering from acute, life-threatening blood pressure spikes (over 200 mmHg).

The Fact: There is NO WARNING in the official packaging about this cardiovascular shock.

The Fact: There is NO PROTOCOL provided to doctors or patients on how to safely discontinue the drug.

2. The Failure of the Medical Duty to Warn
In many cases, including my sister's in Munich, physicians have provided ZERO WARNING about these risks. Whether this silence is due to ignorance or "incentives" from pharmaceutical marketing, the result is the same: the patient is left defenseless. A doctor who prescribes a potent hormonal drug without explaining the risks of cessation is violating the most basic principle of medicine: Primum non nocere (First, do no harm).

3. Global Litigation and Accountability
This is not just an "adverse event"; it is a systemic failure. Legal teams globally, including major firms in the U.S. and Germany, are now mobilizing. The focus is simple: Product Liability and Negligence.

If a manufacturer knows of a risk and hides it, they are liable.

If a doctor fails to warn a patient about a life-threatening rebound effect, they are complicit.

4. A Call for Transparency
Human lives are not test subjects for corporate greed. We demand full disclosure of all cardiovascular data related to Semaglutide withdrawal. We demand that every patient be informed—not just about how to start the drug, but how to survive stopping it.

The "Safety" claims are a lie. The "Failure to Warn" is real. We will not be silent while people’s lives are put at risk for a bottom line.

Institutional Risk Analysis
SUBJECT: WEGOVY (SEMAGLUTIDE) SYSTEMIC RISK ALERT – THE WITHDRAWAL HYPERTENSION TRAP

As of March 2026, the institutional narrative surrounding GLP-1 agonists is shifting from growth euphoria to significant product liability exposure. While the market has priced in gastrointestinal side effects, it has fundamentally overlooked the "Rebound Hypertension" phenomenon following therapy cessation.

1. The "Failure to Warn" Liability:
Current litigation (MDL 3094) targets Novo Nordisk for failing to adequately disclose severe adverse events. Crucially, the official label focuses on hypotension (low blood pressure) during use but remains silent on the risk of hypertensive crisis (BP > 200 mmHg) upon withdrawal. This regulatory "blind spot" is a primary trigger for catastrophic injury claims.

2. Sympathetic Overdrive & Cardiovascular Instability:
Clinical evidence suggests that sudden discontinuation of semaglutide induces a state of internal imbalance. The body, previously under artificial metabolic control, reacts with a "rebound" effect, causing acute vasoconstriction and life-threatening blood pressure spikes. For investors, this represents an unpriced "Tail-Risk": if regulators mandate black-box warnings for withdrawal risks, the lifetime value (LTV) of the user base collapses.

3. Algorithmic Sentiment & Litigation Escalation:
Algorithms tracking German and U.S. court filings (including Landgericht München) are detecting a surge in "Non-GI" injury reports. The divergence between sales growth and safety signals is at a critical juncture. Hedge funds should anticipate significant legal reserves being set aside, potentially impacting free cash flow and dividend stability through 2027.

Hims & Hers Shares Jump on Analyst Upgrades After Novo Nordisk PartnershipMarch 10, 2026 11:44 AM
IH Market News
Hims & Hers Health (NYSE:HIMS) shares climbed about 10% on Tuesday, extending Monday’s sharp rally of nearly 49% after analysts upgraded the stock following the company’s newly announced partnership with Novo Nordisk (NYSE:NVO).The collaboration, unveiled Monday, enables Hims & Hers to offer commercially available doses of Ozempic and Wegovy—including a newly developed pill formulation—as part of an expanded weight-loss treatment strategy centered on GLP-1 therapies. As part of the agreement, Novo Nordisk has also withdrawn its lawsuit against Hims & Hers.BofA Securities analyst Allen Lutz upgraded the stock from Underperform to Neutral and raised his price target to $23.00 from $12.50. The revised valuation reflects a 23x CY26E EV/EBITDA multiple that now factors in expected GLP-1-related revenue.Citi analyst Daniel Grosslight also lifted his rating to Neutral and increased his price target to $24 from $13.25. Grosslight noted that the agreement requires Hims & Hers to end its mass-personalization model, allowing only a limited group of customers to remain on compounded GLP-1 treatments. He also said Novo Nordisk dropping the lawsuit “significantly diminishes legal risk.”Earlier, Needham analyst Ryan MacDonald upgraded the stock from Hold to Buy with a $30.00 price target, saying the partnership removes key legal overhangs and materially reshapes the company’s weight-loss strategy and long-term growth outlook.The agreement also allows Hims & Hers to offset potential revenue losses tied to compounded GLP-1 medications by replacing them with branded offerings through its partnership with Novo Nordisk, although the company will face tighter limits on its compounding operations.Hims & Hers shares finished Monday’s session at $22.16.Hims & Hers stock priceNovo Nordisk stock price

Original: Hims & Hers Shares Jump on Analyst Upgrades After Novo Nordisk Partnership

Novo Nordisk Shares Slide After FDA Issues Warning LetterMarch 10, 2026 11:40 AM
IH Market News
Novo Nordisk A/S (NYSE:NVO) shares declined 2.8% on Tuesday after the company disclosed it had received a warning letter from the U.S. Food and Drug Administration related to shortcomings in postmarketing adverse event reporting.The FDA issued the letter on March 5, 2026, following an inspection of Novo Nordisk Inc. conducted between January 13 and February 7, 2025. Regulators said the review uncovered significant violations tied to the reporting of adverse drug experiences associated with products including semaglutide, liraglutide, nedosiran sodium and estradiol.According to the agency, the company did not maintain adequate written procedures governing the monitoring, collection, evaluation and reporting of adverse drug experiences after products had entered the market. Investigators found that Novo Nordisk and certain contractors failed to submit reports of serious and unexpected adverse events to the FDA within the mandated 15-day reporting window.The warning letter also noted that the company’s procedures permitted some adverse event reports to be rejected or cancelled when reporters believed the event was not linked to the product, a practice the FDA said conflicts with regulatory requirements. During its review, the agency identified several cases in which serious adverse events—including stroke, death and suicidal ideation—were either reported late or invalidated even though valid patient identifiers were present.Regulators further stated that Novo Nordisk did not consistently investigate adverse events requiring 15-day alert reports in a timely manner. In some instances, follow-up was delayed because the company required consent from reporters before conducting additional investigation.Novo Nordisk has submitted several responses to the FDA between March 2025 and January 2026 outlining corrective measures. These included updating internal procedures, conducting retrospective reviews of reported cases and shifting safety case intake to specialized in-house patient safety personnel.However, the FDA said the responses did not provide enough detail to confirm that the corrective actions would effectively prevent similar issues in the future.The agency has requested that Novo Nordisk submit a detailed response within 15 business days describing the steps it will take to address the violations and prevent them from recurring.Novo Nordisk stock price

Original: Novo Nordisk Shares Slide After FDA Issues Warning Letter

Behind the GLP-1 Hysteria: Why the "Investment of the Decade" is a Ticking Time Bomb
As someone who closely monitors market trends and their real-world consequences, it is time to say what many managers are afraid to admit: The hysteria surrounding GLP-1 medications (Ozempic, Wegovy, Zepbound) has reached a tipping point of unsustainability. While massive capital shifts into Big Pharma, ignoring the human cost of this "success" is creating a systemic risk that will eventually cost investors billions.

1. Hysteria vs. Reality
The hype surrounding these drugs is not purely medical—it is manufactured market sentiment. The promise of a world without obesity overnight attracted capital but ignored fundamental biology. The expectation that millions will remain indefinitely on a therapy costing thousands per month, while enduring devastating effects on their bodies, is mathematically and humanly unsustainable.

2. The Wave of Litigation: Numbers That Don't Lie
Investors prioritize data, so here is the data hidden in the footnotes: as of March 2026, over 4,400 lawsuits have been filed against leading manufacturers. This is not "legal noise"—it is the beginning of a systemic collapse of trust. The litigation focuses on the failure to warn and the conscious concealment of risks, placing Big Pharma in the same precarious position once held by the tobacco and opioid industries.

3. The True Cost to the Consumer (Without the Gloss)
What marketing algorithms call "side effects" are, in real life, permanent disabilities. We are seeing a growing population of users who curse the day they began treatment because they were met with:

Gastroparesis (Stomach Paralysis): A condition where the organs literally cease to function.

Permanent Blindness (NAION): Sudden vision loss that no profit margin can justify.

Systemic Collapse: Chronic pain, blood pressure dysregulation, and metabolic chaos that persists even after the medication is discontinued.

4. A Message to Managers and Big Investors
Smart capital does not stay in a bubble that is bursting due to public health liabilities. The current surge in pharmaceutical stocks is based on a "subscription to sickness," but the wave of injured users heading to the courtrooms will turn that growth into massive settlements and credit downgrades.

Exercise caution. Biology always outlasts marketing. In this case, the price of defeat will be astronomical. It is time to ask: are you investing in health, or in the next greatest litigation scandal of the modern era?

Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platformMarch 9, 2026 6:49 AM
IH Market News
Novo Nordisk (NYSE:NVO) is planning to distribute its weight-loss medications through the telehealth platform operated by Hims & Hers Health (NYSE:HIMS), signaling an unexpected thaw in relations between the companies after a recent legal clash, Bloomberg reported over the weekend.Shares of Hims — which have fallen roughly 51% so far this year — jumped more than 44% in premarket trading Monday as of 09:08 GMT. Meanwhile, Novo Nordisk’s shares in Copenhagen rose about 1%.According to the report, the companies could unveil a new partnership as soon as Monday. The arrangement would allow Novo’s obesity treatments to be sold through Hims’ platform, restoring a relationship that broke down last year after Novo accused the telehealth provider of continuing to promote compounded versions of its medications.The renewed collaboration follows months of escalating tensions. In February, Novo filed a lawsuit against Hims after the telehealth company introduced a copycat version of its oral Wegovy weight-loss pill, arguing the product violated patents linked to the active ingredient used in its blockbuster drugs Ozempic and Wegovy.Leerink analyst Michael Cherny said the development was “both a surprise and an unabashed positive for HIMS’ stock,” noting that it could help avoid what had appeared likely to become “a protracted legal process that could include a full trial.”Still, Cherny cautioned that “even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential and thus maintain our Market Perform rating.”In a separate research note, Morgan Stanley analyst Craig Hettenbach said a partnership between the companies could remove one of the biggest uncertainties hanging over the stock — legal and regulatory risks related to the company’s weight-loss offerings. He added that “any reduction in those risks could lead to a strong rebound in the heavily shorted stock.”During recent supply shortages, telehealth providers such as Hims sold lower-cost compounded versions of weight-loss treatments developed by Novo Nordisk and Eli Lilly. Although those shortages have since been resolved and companies were expected to halt the sale of such copies, some providers have continued offering them by adjusting dosages or altering ingredients to distinguish them from the branded drugs, the report said.Novo Nordisk stock priceHims & Hers stock price

Original: Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platform

Novo Nordisk gains after FDA issues warnings to telehealth firms over compounded GLP-1 drugsMarch 4, 2026 6:23 AM
IH Market News
Shares of Novo Nordisk (NYSE:NVO) climbed more than 3% on Wednesday after the U.S. Food and Drug Administration sent warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 medications, including versions of the company’s semaglutide and Eli Lilly’s tirzepatide.According to the FDA, the companies breached regulations by promoting compounded products as “generic Zepbound” or “generic Mounjaro,” the brand names for Lilly’s tirzepatide. Some firms also marketed the medications under proprietary brand names without clearly stating that they were produced by compounding pharmacies.The agency emphasized that compounded medicines are not approved by the FDA and should not be considered equivalent to generic drugs. Companies that received warning letters have 15 working days to submit a written response.“Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” FDA Commissioner Marty Makary said in a statement on Tuesday.The move represents the second batch of warning letters since the regulator began tightening oversight of misleading direct-to-consumer pharmaceutical advertising in September.The FDA said it has issued thousands of such warnings to pharmaceutical and telehealth companies during the past six months—more than the total number sent in the entire previous decade.Citi Research noted that the letters may carry greater significance given the increasingly strict regulatory climate.The brokerage highlighted the FDA’s decision to refer Hims & Hers to the Department of Justice in early February as an indication that stronger enforcement measures could follow, particularly as broader Medicare access to GLP-1 treatments is expected in the second quarter.Citi also said Commissioner Makary has separately indicated plans to restrict the active pharmaceutical ingredients used in compounded GLP-1 products, a step that could further limit the market for compounding pharmacies.Novo Nordisk stock price

Original: Novo Nordisk gains after FDA issues warnings to telehealth firms over compounded GLP-1 drugs

Novo Nordisk shares extend losses following analyst downgradesFebruary 24, 2026 6:06 AM
IH Market News
Novo Nordisk (NYSE:NVO) continued to face selling pressure after JPMorgan downgraded the stock to Neutral from Overweight, citing disappointing late-stage REDEFINE-4 trial results for its obesity treatment CagriSema, which indicated weaker competitiveness compared with Eli Lilly’s (NYSE:LLY) Zepbound.The bank also reduced its price target to 250 Danish crowns from 350, while analysts at Deutsche Bank and Kepler Cheuvreux similarly lowered their ratings on the shares.Novo Nordisk stock fell about 3.61% in Copenhagen trading, last changing hands at 243.60 DKK per share.JPMorgan analyst Richard Vosser said the latest trial outcomes revealed a less compelling weight-loss profile compared with Lilly’s Zepbound in obesity treatment, along with a more modest glucose-lowering effect in patients with Type 2 diabetes, prompting revisions to the firm’s outlook.Vosser noted that earlier forecasts had already assumed limited market penetration for CagriSema following previous trial data, but he now anticipates “a more challenging uptake for the product given inferiority to Zepbound.”Consequently, JPMorgan reduced its CagriSema revenue projections by 40%–63% for the 2027–2030 period and lowered amycretin estimates by 1%–23% to account for weaker anticipated pricing. These revisions resulted in cuts of 2%–16% to group sales forecasts for 2026–2030 and reductions of 2%–17% in adjusted earnings per share expectations.The analysts now estimate Novo’s earnings outlook for 2026–2030 to be between 5% and 21% below Bloomberg consensus forecasts, with projected EPS growth broadly aligned with other large-cap European pharmaceutical peers.Vosser added that the CagriSema profile “seems hard to recover from inferiority result in REDEFINE 4,” despite weight-loss results of roughly 20%, which still exceed Wegovy but fall short of Zepbound’s 23%.He maintained a more positive long-term view on amycretin, particularly its potential as an oral therapy, though he cautioned that investor sentiment will likely hinge on Phase III trial results expected between 2028 and 2029.In a separate research note, Barclays adopted a more optimistic short-term stance on the rollout of Oral Wegovy, saying early prescription data are “encouraging.” The bank reported that Week 7 prescriptions reached roughly 48,000, representing a 12% week-on-week increase, while daily TRx figures showed “a strong ramp continues.”Novo Nordisk stock price

Original: Novo Nordisk shares extend losses following analyst downgrades

Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVOFebruary 23, 2026 12:00 PM
Business Wire
The DJS Law Group announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) for violations of the securities laws.


INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk announced on February 23, 2026, that its open-label phase 3 trial comparing its CagriSema drug for weight loss against Eli Lilly’s tirzepatide “did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to tirzepatide after 84 weeks.” Based on this news, shares of Novo Nordisk fell by more than 15% in premarket trading on February 23, 2026.


If you are a shareholder who suffered a loss, contact us to participate.


WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.


This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223425507/en/
David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com


Original: Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

Novo Nordisk Shares Slide After Obesity Drug Misses Key Trial Goal Against Rival TreatmentFebruary 23, 2026 6:02 AM
IH Market News
Shares of Novo Nordisk (NYSE:NVO) listed in Copenhagen dropped more than 10% in mid-morning trading on Monday after the pharmaceutical group revealed that its experimental obesity therapy, CagriSema, failed to meet a primary objective in a head-to-head open-label study.The trial aimed to demonstrate that CagriSema performed at least as well as Eli Lilly’s competing treatment, Tirzepatide, in reducing body weight.In a statement, Novo said the 84-week study compared a fixed-dose version of CagriSema with Tirzepatide and found that patients receiving CagriSema achieved average weight loss of 23%. Participants treated with Tirzepatide recorded weight reductions of 25.5%, according to the company.“The trial did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to tirzepatide after 84 weeks,” Novo said.Novo Nordisk, whose blockbuster medicines Wegovy and Ozempic previously helped secure a leading position in the rapidly expanding obesity treatment market, has faced intensifying competition from Eli Lilly as well as telehealth providers offering cheaper copycat alternatives. The company’s shares fell 49% during 2025.Last week, Novo announced plans to nominate two experienced pharmaceutical executives to its board, introducing new leadership figures following a broader governance reshuffle.Lars Rebien Sorensen has taken over as board chairman, strengthening the influence of a figure who had previously criticized management for responding too slowly to competitive pressures in the U.S. market.CagriSema has already been submitted to the U.S. Food and Drug Administration for approval in weight management, with Novo expecting a regulatory decision by late 2026.Novo Nordisk stock price

Original: Novo Nordisk Shares Slide After Obesity Drug Misses Key Trial Goal Against Rival Treatment

NOV presented an offer to one of the company is on the panel... wonder who it was???

When optical cheapness replaces real value

Shares of Pfizer and Novo Nordisk are increasingly viewed through a similar lens: significant declines from historical highs and nominally lower prices that many interpret as opportunity. However, a lower price alone does not confirm that the repricing process has been completed.

In Pfizer’s case, prolonged consolidation following a sharp decline suggests that the market may still be searching for a new, sustainable earnings baseline. Pandemic-related revenues have normalized, while the current pipeline has yet to provide clear near-term replacement cash flows. In such environments, time often works against valuation rather than supporting it, as investor patience gradually erodes.

Novo Nordisk presents a different narrative but a comparable structural risk. Years of exceptional performance were accompanied by valuations that priced in near-perfect future outcomes: extended GLP-1 hyper-growth, limited competition, and durable pricing power. While valuation premiums have compressed, there is limited evidence that expectations have fully normalized, particularly amid intensifying competition and reduced visibility of future blockbuster catalysts beyond the existing segment.

The common risk across both cases is misinterpreting optical cheapness as structural value. Prolonged sideways price action without a confirmed trend reversal does not necessarily indicate accumulation; it can signal an incomplete repricing phase.

This assessment does not question company quality or long-term relevance. It highlights the distinction between:

a great business
and

an attractive investment at a specific point in the cycle.

In sectors where expectations were elevated for extended periods, market repricing rarely concludes without a phase of genuine discomfort. Overlooking this pattern simply because prices are lower than in the past introduces risk that should not be ignored.

This is not a forecast or an investment recommendation.
It is a risk-focused structural assessment intended to counter optical bias.

Novo Nordisk Takes Legal Action Against Hims & Hers Over Compounded SemaglutideFebruary 9, 2026 10:07 AM
IH Market News
Novo Nordisk (NYSE:NVO) has filed a patent infringement lawsuit against telehealth provider Hims & Hers (NYSE:HIMS) in the United States, targeting the company’s sale and promotion of compounded semaglutide products, according to a statement from the Danish drugmaker.Novo Nordisk alleges that Hims & Hers violated U.S. Patent 8,129,343 by marketing compounded versions of semaglutide that it says copy its FDA-approved diabetes and obesity treatments Wegovy and Ozempic. The company argues that these products are unapproved alternatives promoted outside the FDA’s regulatory framework.The lawsuit seeks a permanent injunction to stop Hims & Hers from selling what Novo Nordisk describes as infringing compounded drugs, along with financial damages.“Hims & Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process,” said John F. Kuckelman, senior vice president at Novo Nordisk.Novo Nordisk said internal tests found that injectable compounded semaglutide products from pharmacies contained impurity levels of up to 86%, while compounded oral versions showed impurities as high as 75%, raising concerns about safety and effectiveness.The legal action follows Hims & Hers’ recent rollout—and subsequent withdrawal—of its “Compounded GLP-1 Pill,” which came shortly after Novo Nordisk launched its Wegovy pill, described as the first FDA-approved GLP-1 pill for weight loss.According to the statement, several medical organizations, including the American Medical Association, the American Diabetes Association and the Endocrine Society, have also raised concerns about the use of compounded GLP-1 drugs.Novo Nordisk added that all doses of Wegovy and Ozempic are currently available nationwide across the U.S.Novo Nordisk stock priceHims & Hers stock price

Original: Novo Nordisk Takes Legal Action Against Hims & Hers Over Compounded Semaglutide

$NVO - Details on the share repurchase program.
Novo wil repurchase up to 3.8B DKK (about €500M) shares in the period between the 4th of February and the 4th of March. 
This is part of the 15B DKK program (about 1% of total market cap and worth about €2B) that will be finalized next year on the 4th of February. 
Buybacks already began last week. 
They purchased between 200k and 280k shares per day.

Novo Nordisk Shares Surge as Hims Drops $49 Weight-Loss Pill Under Regulatory PressureFebruary 9, 2026 6:03 AM
IH Market News
Novo Nordisk (NYSE:NVO) rallied strongly on Monday after telehealth provider Hims Hers Health (NYSE:HIMS) withdrew its recently launched $49 compounded weight-loss pill over the weekend, following pushback from Novo Nordisk and the U.S. Food and Drug Administration.Novo Nordisk shares climbed more than 8% in Copenhagen trading by 04:48 ET (09:48 GMT), while its U.S.-listed stock was up about 6.5% in premarket action. In contrast, Hims Hers shares fell sharply, dropping around 14% before the opening bell.Hims had introduced the pill last Thursday using semaglutide, the active ingredient in Novo’s blockbuster obesity and diabetes treatments Wegovy and Ozempic. The launch quickly drew objections from both Novo Nordisk and regulators. By Saturday, Hims said it would halt the product after holding “constructive conversations with stakeholders.”Novo’s shares had already risen more than 5% on Friday after FDA Commissioner Marty Makary signalled that the agency would step up scrutiny of unauthorised compounded GLP-1 drugs, which have weighed on Novo’s pricing power in the obesity and diabetes markets.The FDA said it plans to restrict the use of GLP-1 ingredients in non-approved compounded medicines marketed as alternatives to authorised treatments, citing quality and safety risks as well as potential violations of federal law. Novo later confirmed it would pursue legal action against Hims over its efforts to sell compounded versions of the drug.“The plans to launch compounded Oral Wegovy in the U.S., at only $49/mo had raised some initial concerns,” Barclays analyst James Gordon wrote in a note. A spokesperson for Eli Lilly (NYSE:LLY) said the company also welcomed the FDA’s move.The rebound in Novo’s share price comes after a sharp selloff last week, when roughly $50 billion was wiped from the Danish drugmaker’s market capitalisation. The company had warned that “unprecedented” pricing pressure would significantly weigh on sales and profits this year.Novo stunned investors by forecasting that both revenue and earnings could fall by as much as 13% in 2026, ending a long streak of double-digit growth. The outlook reflects intensifying competition in the high-margin obesity market as U.S. President Donald Trump pushes to lower drug prices.Novo has also been losing momentum to Eli Lilly, which has taken the lead in U.S. prescription trends and earlier this week projected 2026 profit above Wall Street expectations. Despite Monday’s bounce, Novo shares are still down roughly 2% since the start of the year.Novo Nordisk stock priceHims & Hers stock price

Original: Novo Nordisk Shares Surge as Hims Drops $49 Weight-Loss Pill Under Regulatory Pressure

Just bought $NVO 46.71 way too cheap hit a major support like yesterday if trades sideways or goes up from here check monthly chart yearly hit bottom accumulating now sideways.

Hims & Hers slides after FDA signals crackdown on unauthorized copycat medicinesFebruary 6, 2026 10:45 AM
IH Market News
Shares of Hims & Hers Health (NYSE:HIMS) dropped 10% on Friday after the U.S. Food and Drug Administration warned it would move against companies promoting unapproved versions of prescription drugs, a development that rattled investors just a day after the telehealth group launched a cheaper alternative to a Novo Nordisk (NYSE:NVO) weight-loss treatment.The decline followed comments from FDA Commissioner Dr. Marty Makary, who wrote on social media platform X that the agency “will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products.” Although Hims & Hers was not named directly, the statement came shortly after the company announced it would offer a compounded version of semaglutide priced at $49 for the first month and $99 thereafter under a five-month plan.In contrast, Novo Nordisk shares jumped 7% on Friday, rebounding from losses the previous session that were triggered when Hims & Hers revealed its lower-cost alternative to Novo’s Wegovy.Novo Nordisk pushed back strongly against the move, describing it as “illegal mass compounding that poses a significant risk to patient safety” and saying it would “take legal and regulatory action” against the company. The Danish drugmaker also stressed that only its FDA-approved Wegovy pill incorporates the proprietary SNAC technology required for oral absorption of semaglutide.Reinforcing those concerns, the FDA commissioner cautioned that the agency “cannot verify the quality, safety, or effectiveness of non-approved drugs,” casting doubt over Hims & Hers’ efforts to broaden access to weight-loss medications at prices comparable to a monthly streaming subscription.Hims & Hers stock price

Original: Hims & Hers slides after FDA signals crackdown on unauthorized copycat medicines

Novo shares bounce back as FDA signals tougher stance on weight-loss drug knockoffsFebruary 6, 2026 5:54 AM
IH Market News
Shares of Danish pharmaceutical group Novo Nordisk (NYSE:NVO) rallied on Friday, recovering some of the steep losses suffered earlier in the week after the U.S. Food and Drug Administration indicated it would step up action against the widespread promotion of unapproved copycat medicines.Novo’s American depositary receipts surged more than 7% in premarket trading, while the stock gained over 5% in Copenhagen.The rebound followed two bruising sessions, including an almost 8% slide on Thursday triggered by telehealth company Hims and Hers Health launching a low-cost $49 compounded alternative to Novo’s FDA-approved Wegovy weight-loss drug.“FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,” FDA Commissioner Marty Makary said on X, without naming specific firms.
“The FDA cannot verify the quality, safety or effectiveness of non-approved drugs,” he added.The FDA’s comments came after Novo’s shares had plunged 17% in Copenhagen on Wednesday, when the company issued an early and downbeat outlook for 2026.Novo warned that both sales and operating profit next year are expected to decline by between 5% and 13%, a far weaker projection than the market had been expecting.“In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market,” CEO Mike Doustdar said in a statement.
“However, we are very encouraged by the promising early uptake from the U.S. launch of Wegovy pill, and we remain confident in our ability to drive volume growth over the coming years,” he added.The guidance marked a notable shift for a company that has delivered several years of double-digit revenue and profit growth since Wegovy was launched in 2021, sparking a boom in demand for obesity treatments and helping Novo become Europe’s most valuable listed company in 2024.Novo said the weaker outlook reflects pressure from lower realized prices—especially in the U.S.—intensifying competition, and upcoming patent expiries for semaglutide, the active ingredient in Wegovy and Ozempic, in certain markets outside the United States.Novo Nordisk stock price

Original: Novo shares bounce back as FDA signals tougher stance on weight-loss drug knockoffs

Novo Nordisk Shares Slide After Company Flags Weaker 2026 Sales OutlookFebruary 4, 2026 6:18 AM
IH Market News
Shares in Novo Nordisk A/S (NYSE:NVO) fell sharply after the maker of Wegovy reported fourth-quarter results and issued a downbeat sales outlook for 2026, catching investors off guard.The company said it expects adjusted sales growth in 2026—excluding revenue linked to the reversal of 340B provisions—to range between -5% and -13% at constant exchange rates. This compares with sales growth of 10% in 2025.Management attributed the weaker outlook to a combination of factors, including lower pricing tied to the U.S. “Most Favoured Nations” agreement, patent expiries for the semaglutide molecule in certain international markets, and rising competitive pressures.Novo Nordisk shares ended 14.6% lower in New York trading, while the stock dropped roughly 16% on the Copenhagen exchange on Wednesday.The midpoint of the 2026 sales guidance came in around 8% below market expectations, according to BofA analyst Sachin Jain. Morgan Stanley analyst Thibault Boutherin said the “2026 guide surprised to the downside, confirming our concerns on U.S. prices and mix.”“Our new forecasts are at the top end of the new guidance, but we see downside risks if our volume growth assumptions do not materialise,” Boutherin added.For 2025, Novo reported sales growth of 6% in Danish kroner and 10% at constant exchange rates, reaching DKK 309.1 billion. Operating profit for the year declined 1% in Danish kroner but rose 6% at constant exchange rates to DKK 127.7 billion. Excluding the impact of a company-wide transformation programme, operating profit would have increased by 6% in Danish kroner and 13% at constant exchange rates.Sales from U.S. operations rose 3% in Danish kroner, or 8% at constant exchange rates, in 2025, while international operations delivered growth of 10% in Danish kroner, or 14% at constant exchange rates.Novo Nordisk also announced that Dave Moore, head of U.S. operations, will step down for personal reasons, with Jamey Millar named as his successor.“Pricing concessions weigh on the topline in 2026 as Novo looks for volumes to flow through,” said BMO Capital analyst Evan David Seigerman after the results.“Following Trump MFN deals and new needed efforts to maintain access in the obesity market, Novo now faces extensive pricing headwinds in the US. While early signs of growth exist for the Wegovy pill, concessions for injectable GLP-1s are clearly impacting the topline offsetting gains in the oral market.”The update from Novo Nordisk also weighed on shares of U.S. rival Eli Lilly and Company (NYSE:LLY), which closed 3.9% lower.Novo Nordisk stock price

Original: Novo Nordisk Shares Slide After Company Flags Weaker 2026 Sales Outlook

This stock belongs at $85 / share short term (3 months), $150+ in (2) years.

Going to $100 might have the best money making pill in Pharma history. 

Per CNBC-TV, we may be looking at NVO's newly FDA-approved pill to be used for anxiety/depression. 

https://schrts.co/EVaCuNxr

So based on what you posted in November, what say you now that NVO pill has gotten approval??

Big morming shorting $43 -9%

Sell Novo Nordisk and buy Viking Therapeutics VKTX

https://seekingalpha.com/article/4836794-sell-novo-nordisk-and-buy-viking-therapeutics

Good luck and GOD bless,

WARNING: Weight Loss Injections – A Global Health Risk

Weight loss injections are becoming increasingly popular, but they represent a serious trap for users and a risk to public health. Temporary weight loss conceals long-term consequences: hormonal imbalances, metabolic disruptions, and impairment of vital body functions.

Using these products without professional supervision can lead to severe health complications, increased strain on healthcare systems, and potential legal liabilities for the companies distributing them.

Investors and regulators should be aware that this trend is not merely a temporary market phenomenon – it could trigger a global “red alert” in healthcare and finance due to heightened risks of lawsuits, reputational damage, and regulatory sanctions.

Conclusion: Any signal of rising demand for such products should be treated as an urgent situation. Investments in this area carry high risk, and the potential negative consequences far outweigh short-term profitability.

According to ClinicalTrials.gov, this Friday (9/19/25) is the final data collection date for primary outcome measure.

Does anyone know how long it will take for them to announce a TLR? (Top Line Results)

Also cut 9000 employees from NVO workforce today.